BioSpace News Archive

Preclinical data support the development of KB-3061 as a potential precision medicine treatment for a rare pediatric epilepsy

CPS’ PAInS Program Designed to Help Reduce Opioid Use Through Pharmacist Continuing Education

LimaCorporate is pleased to announce the FDA 510K approval for Smart SPACE Shoulder 3D Planner & 3D Positioner. Smart SPACE is an innovative digital platform developed by TechMah Medical thanks to collaboration with LimaCorporate, who entered into a milestone-based acquisition agreement last year

The first use of serum proteomics data to identify early indicators of response to treatment in a rare, hyperinflammatory, lymphoproliferative disorder (Idiopathic Multicentric Castleman disease) was presented at the 61st Annual Meeting of the American Society of Hematology.

Stadius Biopharma LLC will present data on its fully human antibodies to Candida at the upcoming Antibody Engineering & Therapeutics meeting December 9 – 13, 2019 in San Diego.

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced today that new research utilizing the company’s CELLSEARCH® Circulating Tumor Cell (CTC) test will be featured at the upcoming 2019 San Antonio Breast Cancer Symposium (SABCS).

GVB Biopharma, a leading hemp cannabinoid producer, announced today that its research and development team has identified and isolated a previously unstudied cannabinoid called cannabicitran, or CBT

Funds will address a wide range of health issues, including diabetes and developmental delays in children

Experts at Hackensack Meridian Health John Theurer Cancer Center, a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, participated in 46 studies presented over the last week at the American Society of Hematology’s 61st Annual Meeting & Exposition, held at the Orange County Convention Center in Orlando, FL from December 7-10.

Kite, a Gilead Company (Nasdaq: GILD), and the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW), today announced findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.